AMGEN INC v. SANDOZ INC (2019)

United States Court of Appeals, Federal Circuit.

AMGEN INC., Amgen Manufacturing, Limited, Plaintiffs-Appellants v. SANDOZ INC., Sandoz International GmbH, Sandoz GmbH, Defendants-Appellees

Amgen Inc., Amgen Manufacturing, Limited, Plaintiffs-Appellants v. Sandoz Inc., Sandoz International GmbH, Sandoz GmbH, Lek Pharmaceuticals, D.D., Defendants-Appellees

2018-1551

Decided: September 03, 2019

Before Lourie, O’Malley, and Reyna, Circuit Judges. Nicholas P. Groombridge, Attorney, Jennifer Gordon, Golda Lai, Peter Sandel, Eric Alan Stone, Attorney, Jacob Whitt, Jennifer H. Wu, Attorney, Paul, Weiss, Rifkind, Wharton & Garrison LLP, New York, NY, Lois Kwasigroch, Attorney, Kimberlin L. Morley, Esq., Wendy A. Whiteford, Amgen Inc., Amgen Inc., Thousand Oaks, CA, for Plaintiffs-Appellants Deanne Maynard, Counsel, Brian Robert Matsui, Erik Jeffrey Olson, Esq., Litigation Counsel, Eric C. Pai, Morrison & Foerster LLP, Palo Alto, CA, for Defendants-Appellees

ON PETITION FOR PANEL REHEARING

ORDER

Appellants filed a petition for panel rehearing on June 7, 2019. A response to the petition was invited by the panel and filed by the Appellees on July 29, 2019.

Upon consideration thereof,

It Is Ordered That:

1) The petition for panel rehearing is GRANTED to the extent that the following portion of the opinion at page 11, lines 20–21, is removed:

applies only in exceptional cases and

2) The petition for panel rehearing is otherwise DENIED.

Per Curiam.